Research Article

HEPATITIS B AND C SEROPOSITIVITY IN A COHORT OF HIV-POSITIVE PATIENTS IN ILORIN, NORTH-CENTRAL NIGERIA

Udeze A.O1*, Ali U.M1, Adeoye P.A1, Odugbesi A.E1, Sule W.F2, Okonko I.O3
1 Virology Unit, Department of Microbiology, University of llorin, P.M.B 1515 Ilorin-Nigeria
2 Department of Biological Sciences, College of Science, Engineering and Technology, Osun State University, PMB 4494, Osogbo, Osun State, Nigeria
3 Department of Microbiology, University of Port Harcourt, Choba, P.M.B, 5323 Port Harcourt, River State, Nigeria
* Corresponding author: udeze.ao@unilorin.edu.ng
Published: Aug, 2015
DOI: 10.67614/njm.2015.ncqfs5z9
Pages: 2767-2776

Abstract

Since HIV, HBV and HCV share common routes of transmission and acquisition, HIV infected patients are likely exposed to HB and C viruses. We hypothesised that there was no difference between prevalence rate of HB and C infections among HIV-infected patients accessing healthcare at HIV and AIDS section of University of Ilorin Teaching Hospital, Ilorin, Nigeria. This is a hospital-based cross sectional study. After obtaining ethical approval, we consecutively selected consenting 356 participants from whom we obtained pertinent socio demographic data using questionnaire forms; after which we aseptically collected blood samples and prepared plasma from each. The latter were tested, using ELISA, for presence of HBsAg and anti-HCV antibody. The results were analyzed using t-test and binary logistic regression. Of the 356 (128 males and 228 females: age range 7 months-70 years, mean age 36.5 years) HIV-infected participants, 114 (32.0%) and 14 (3.9%) were respectively positive for HBsAg and anti-HCV antibody; these respectively represented dual HIV-HBV and HIV-HCV infection rates. The HIV-positive participants had more than 11 times (p=0.001) likelihood of being HBsAg positive than being anti-HCV antibody positive. Group-specific prevalence rate was also higher for HIV-HBV dual infection. Conclusively, the HIV-infected participants had significantly higher HB rate compared to HC, this was suggestive of higher infectiousness of HBV and greater exposure to HBV than HCV. The only variable predictive of HIV-HCV or HIV HBV dual infection was education. But, occupation and history of blood transfusion were respectively predictive of HIV-HBV and HIV-HCV dual infection among the study participants.

Keywords

dual infection hepatitis B hepatitis C HIV-positive Nigeria seropositivity

References

  1. Aceijas, C. And Rhodes, T. (2007). Global estimates of prevalence of HCV infection among injecting drug users. Int. J. Drug Policy 18: 352–358.
  2. Adewole, O.O., Anteyi, E., Ajuwon, Z., Wada, I., Elegba, F., Ahmed, P., Betiku, Y., Okpe, A., Eze, S., Ogbeche, T. and Erhabor, G.E. (2009). Hepatitis B and C virus co-infection in Nigerian patients with HIV infection. J Infect Dis Cities 3(5): 68-75.
  3. Agbaji, O., Badung, B., Idoko, J. and Kanki, P. (2005). Seroprevalence of HBV and HCV infection among HIV-infected patients attending the antiretroviral clinic in (JUTH) Jos, Nigeria. 3d International AIDS Society Conference on HIV pathogenesis and treatment. Rio de Janeiro July 24-27.
  4. Alao, O., Okwori, E., Egwu, C. and Audu, F. (2009). Seroprevalence of Hepatitis B Surface Antigen among Prospective Blood Donors in an Urban Area of Benue State. The Internet Journal of Hematology, 5(2).
  5. Araoye, M.O. (2003). Research Methodology with Statistics for Health and Social Sciences. Nathadex Publishers. Page 117-120.
  6. Centers for Disease Control and Prevention (1998). Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR, 47 (No. RR-19):1-33.
  7. Denue, B.A., Ajayi, B., Abje, A.U., Bukar, A.A., Akawu, C., Ekong, E. and Alkali, M.B. (2012). A survey of hepatitis B and C virus prevalence in human immunodeficiency virus positive patients in a tertiary health institution in North Eastern Nigeria. International Journal of Medicine and Medical Sciences 4(1): 13-18.
  8. Dieterich, D.T., Fischl, M. and Sepulveda, G. (2002). The safety/efficacy of protease inhibitors (PIs) in hepatitis C coinfected patients, 1729. Abstr. 42nd Intersci conf. Antimicrob. Agents Chemother. American Society for Microbiology Washington DC.
  9. Federal Ministry of Health Nigeria. National HIV/AIDS and Reproductive Health Survey. Federal Ministry of Health Abuja, Nigeria. 2004: 1-4.
  10. Forbi, J.C., Gabadi, S., Alabi, R., Iperepolu, H.O., Pam, C.R., Entonu, P.E., Aqwale, S.M. (2007). The role of triple infection with hepatitis B virus, hepatitis C virus, and human immunodeficiency virus (HIV) type-1 on CD4+ lymphocyte level in the highly HIV infected population of North-Central Nigeria. Mem Inst. Oswaldo Cruz, vol 102 no 4 Rio de Janeiro.
  11. Harania, R.S., Karuru, J., Nelson, M., Stebbing, J. (2008). HIV, hepatitis B and C co-infection in Kenya. AIDS 22(18): 1221-2.
  12. Hershow, R.C., Riester, K.A., Lew, J., Quinn, T.C., Mofenson, L.M., Davenny, K., Cotton, D., Hanson, I.C., Hillyer, G.V., Tan, H.B., Thomas, D.L. (1997). Increased vertical transmission of human immunodeficiency virus from hepatitis C virus coinfected mothers. Women and infants transmission study. J Infect Dis 176: 414-20.
  13. Ho, M.S., Hsu, C.P., Yuh, Y., et al. (1997). High rate of hepatitis C virus infection in an isolated community: Persistent hyperendemicity or period related phenomena? J Med Virol 52:370–376.
  14. Inyama, P.U., Uneke, C.J., Anyanwu, O.M., Anyawu, G.I., Njoku, O.M., J.H. and Idoko, J.A. (2005). Prevalence of antibodies to Hepatitis C virus among Nigerian patients with HIV infection. Online j Health and Allied Sci., 2:2. www.ojhas.org/issue_14/2005-2-2.htm. retrieved 2009 April.
  15. Kim, J.H., Psevdos, G., Suh, J., Sharp, V.L. (2008). Co-infection of hepatitis B and hepatitis C virus in human immunodeficiency virus infected patients in New York City, Unites States. World J Gastroenterol. 14(43): 6689-93.
  16. Lowe, D. and Cotton, R. (1999). Hepatitis C: a review of Australia's response. Canberra: Publications Production Unit, Commonwealth Department of Health and Aged Care, Commonwealth of Australia.
  17. Maddava, V., Burgess, C., Drucker, E. (2002). Epidemiology of chronic hepatitis co-infection in sub-Saharan Africa. Lancet, Infectious disease 2:293-302.
  18. Maier, I. and Wu, G.Y. (2002). Hepatitis C and HIV co-infection: a review. World J. Gastroenterol. 8: 577–579.
  19. Mutimer, D.J., Olomu, A., Skidmore, S., Olomu, N., Ratcliffe, D., Rodgers, B., Mutimer, H.P., Gunson, B.K. and Elias, E. (1994). Viral hepatitis in Nigeria-sickle cell disease and commercial blood donors. Q J Med 87:407-11.
  20. Nunez, M., Lana, R., Mendoza, J., Martin-Carbonero, L. and Soriano, V. (2001). Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J. Acquir Immune Defic. Syndr. 27:426-431.
  21. Nwokedi, E.E., Epopves, M.A. and Dutse, A.I. (2006). Human immunodeficiency virus and hepatitis C virus infection among patients in Kano, Nigeria. Niger J Med. 15(3):227-9.
  22. Odemuyiwa, S.O., Mulders, M.N., Oyedele, O.I., Ola, S.O., Odaibo, G.N., Olaleye, D.O., and Muller, C.P. (2001). Phylogenetic analysis of new hepatitis C virus isolates from Nigeria supports endemicity of genotype E in West Africa. J Med Virol 63: 463-469.
  23. Olatunji, O.P. and Iseniyi, J.O. (2008). Hepatitis B and C viruses' co-infection with human immunodeficiency virus infected patients at UITH, Ilorin. Nig Med Pract. 54(1):8-10.
  24. Olubuyide, I.O., Ola, S.O., Aliyu, B., Dosumu, O.O., Aritiba, J.T., Olaleye, D.O., Odaibo, G.N., Odemuyiwa, S.O., and Olawuyi, F. (1997). Hepatitis B and C in doctors and dentists in Nigeria. Quarterly J Med, 90:417-422.
  25. Otegbayo, J.A., Taiwo, B.O., Akingbola, T.S., Odaibo, G.N., Adedapo, K.S., Penugonda, A.S., Adewole, I.F., Olaleye, D.O., Murphy, R. and Kanki, P. (2008). Prevalence of Hepatitis B and C seropositivity in a Nigerian cohort of HIV-infected patients. Annals of Hepatology 7(2):152-156.
  26. Pallas, J.R., Farinas-Alvarez, C., Prieto, D., and Delgado-Rodriguez, M. (1999). Coinfections by HIV, hepatitis B and hepatitis C in imprisoned injecting drug users. Eur J Epidemiol 15:699-704.
  27. Petoumenos, K. and Ringland, C. (2005). Australian HIV Observational Database. Antiretroviral treatment change among HIV, hepatitis B virus and hepatitis C virus co-infected patients in the Australian HIV Observational Database. HIV Med. 6(3): 155-63.
  28. Qurishi, N., Kreuzberg, C., Luchters, G., Effenberger, W., Kupfer, B., Sauerbruch, T. et al. (2003). Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C coinfection. Lancet 362: 1708-1713.
  29. Sagoe, K.W., Dery, V., Ziga, F., Lartey, M., Adiku, T.K. and Seshi, M. (2012). Prevalence and impact of hepatitis B and C virus co-infections in antiretroviral treatment naive patients with HIV infection at a major treatment centre n Ghana. J Med Virol. 84(1): 6-10.
  30. Santiago-Munoz, P., Roberts, S., Sheffield, J., McElwee, B. and Wendel, G.D. (2005). Prevalence of hepatitis B and C in pregnant women who are infected with human immunodeficiency virus. Am J Obstet Gyn 193 (Suppl. 3):1270.
  31. Saves, M., Vandoren, S., Daucourt, V., Marimoutou, C., Dupon, M., Couzigou, P., Bernard, N., Mercie, P. and Dabis, F. (1999). Severe hepatic cytolysis: incidence and risk factors in patients treated with antiretroviral combinations. AIDS 13:1424.
  32. Segurado, A.C., Braga, P., Etzel, A. and Cardoso, M.R. (2004). Hepatitis C virus coinfection in a cohort of HIV-infected individuals from Santos Brazil: seroprevalence and associated factors. AIDS Patient Care STDS. 18: 135-43.
  33. Seme, K., Lunar, M.M., Tomazic, J., Vidmar, L., Karner, P., Maticic, M., et al. (2009). Low Prevalence of hepatitis B and C infections among HIV-infected individuals in Slovenia: a nation-wide study, 1986-2008. Acta Dermatovenerol Alp Panonica Adriat. 18(4): 153-6.
  34. Sirisena, N.D., Njoku, M.O., Idoko, J.A., Isamade, E., Barau, C., Jelpe, D., Zamani, A. and Otowo, S. (2002). Carriage rate of hepatitis-B surface antigen (HBsAg) in an urban population in jos Plateau State, Nigeria. Niger Postgrad Med J 9: 7-10.
  35. Soriano, V., Sulkowski, M., Bergin, C., Hatzakis, A., Cacoub, P., Aapro, C., Cargnel, A., Mauss, S., Dieterich, D., Moreno, S., Ferrari, C., Poynard, T. and Rockstroh, J. (2002). Editorial review. Care of patients with chronic hepatitis C and HIV coinfection: recommendations from the HIV-HCV International Panel. AIDS 16:813-828.
  36. Stubbe, L., Soriano, V., Antunes, F., et al. (1998). Hepatitis C in the EuroSIDA cohort of European HIV-infected patients: prevalence and prognostic value in: Program and abstract of the 12th world AIDS conference; June 28-July 3, Geneva. Abstract 22226.
  37. Stud, A., Singh, J., Dhiman, R.K., Wanchu, A., Singh, S., Chawia, Y. (2001). Hepatitis B virus co-infection in HIV infected patients. Trop Gastroenterol. 22(2):90-92.
  38. Udeze, A.O., Aliyu, A.S., Kolawole, O.M., Okonko, I.O., Sule, W.F. and Akanbi, K. (2012). Hepatitis B surface antigenaemia and risk factors of transmission among apparently healthy students of University of Ilorin, Ilorin-Nigeria. Scientia Africana 11(2):1-8.
  39. Uneke, C.J., Ogbu, O., Inyama, P.U., Anyanwu, G.I., Njoku, M.O. and Idoko, J.H. (2005). Prevalence of hepatitis-B surface antigen among blood donors and human immunodeficiency virus-infected patients in Jos, Nigeria. Mem Inst Oswaldo Cruz 100: 13-16.
  40. Verucchi, G., Calza, L., Manfredi, R. and Chiodo, F. (2004). Human immunodeficiency virus and hepatitis C virus coinfection: epidemiology, natural history, therapeutic options and clinical management. Infection 32: 33-46.
How to Cite

A.O, U., U.M, A., P.A, A., A.E, O., W.F, S., & I.O, O. (2015). HEPATITIS B AND C SEROPOSITIVITY IN A COHORT OF HIV-POSITIVE PATIENTS IN ILORIN, NORTH-CENTRAL NIGERIA. Nigerian Journal of Microbiology, 28(1), 2767-2776. https://doi.org/10.67614/njm.2015.ncqfs5z9

U. A.O, A. U.M, A. P.A, O. A.E, S. W.F, and O. I.O, "HEPATITIS B AND C SEROPOSITIVITY IN A COHORT OF HIV-POSITIVE PATIENTS IN ILORIN, NORTH-CENTRAL NIGERIA," Nigerian Journal of Microbiology, vol. 28, no. 1, pp. 2767-2776, August 2015. doi: 10.67614/njm.2015.ncqfs5z9

Share this article:
Facebook X / Twitter LinkedIn
Download PDF View Full Text (PDF) Back to Articles